Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings

摘要: The primary objective of this article is to review information pertinent and emphasize the seriousness a potential adverse monoamine oxidase inhibitor (MAOI)-serotonin uptake interaction by considering, within context preclinical data, clinical cases in which an MAOI fluoxetine hydrochloride, specific serotonin inhibitor, were administered close temporal proximity. Clinical identified spontaneous event reports submitted voluntarily Eli Lilly Company through its drug surveillance program interactions published scientific literature. A discussion eight selected acute reactions (seven with fatal outcomes; one favorable response after cyproheptadine therapy) reported was initiated concurrently or shortly discontinuation data suggest possible role and/or serotonin-dopamine hypermetabolic state that may occur when are coadministered, although alternative etiologic processes as well. Data reviewed reinforce idea administration proximity contraindicated.